FDA & Government News

July 22, 2026

Trump’s Personnel Agency Says It Will Remove Some Identifying Info as It Sweeps Up Medical Records

“Clearly, this administration has not earned our trust with Americans’ sensitive data."

Conexiant

July 16, 2026

FDA Approves First Oral PCSK9 Inhibitor

Merck reported placebo-adjusted LDL-C reductions of 56% and 59% at week 24 in two phase 3 CORALreef trials supporting the approval.

Conexiant

July 16, 2026

Oral Aleniglipron Reduced Weight at 36 Weeks

In a phase 2b trial, the highest dose produced an estimated 12% mean weight reduction vs 1% with placebo, although gastrointestinal adverse events were common.

Conexiant

July 10, 2026

10 CMS and FDA Actions Affecting Care in 2026

From Medicare payment updates to drug approvals and device access, these federal actions may affect reimbursement, prescribing, patient access, and clinical workflows.

Conexiant

July 09, 2026

Top 10 CDC Updates Physicians Should Know

Recent CDC advisories, testing updates, and immunization recommendations highlight developments in infectious diseases, immunization, and diagnostic testing relevant to physicians across multiple specialties.

Conexiant

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.

July 01, 2026

Breast Cancer: Palbociclib-Based Regimen Approved for HR-Positive, HER2-Positive Metastatic Disease

The U.S. Food and Drug Administration (FDA) has approved palbociclib (Ibrance) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult...

The ASCO Post

July 01, 2026

Breast Cancer: Palbociclib-Based Regimen Approved for HR-Positive, HER2-Positive Metastatic Disease

The ASCO Post

June 29, 2026

FDA Approves New Treatment for Thyroid Eye Disease

Phase 3 THRIVE and THRIVE-2 trials supported approval following improvements in proptosis and diplopia in active and chronic disease.

Conexiant

June 26, 2026

FDA Monthly Preview: Key July Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

Conexiant

June 24, 2026

FDA Approves First Therapy to Reduce Pancreatitis Risk

In two placebo-controlled trials, triglyceride levels declined by up to 72% compared with placebo.

Conexiant

CGM Linked to More Time in Range

FDA & Government News

Trump’s Personnel Agency Says It Will Remove Some Identifying Info as It Sweeps Up Medical Records

FDA Approves First Oral PCSK9 Inhibitor

Oral Aleniglipron Reduced Weight at 36 Weeks

10 CMS and FDA Actions Affecting Care in 2026

Top 10 CDC Updates Physicians Should Know

Daily News

Breast Cancer: Palbociclib-Based Regimen Approved for HR-Positive, HER2-Positive Metastatic Disease

Breast Cancer: Palbociclib-Based Regimen Approved for HR-Positive, HER2-Positive Metastatic Disease

FDA Approves New Treatment for Thyroid Eye Disease

FDA Monthly Preview: Key July Decisions to Watch

FDA Approves First Therapy to Reduce Pancreatitis Risk

Recommendations

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Trending Now

CGM Linked to More Time in Range

Trending Now

Find topic & conditions by first letter

Compendium

Inside Dental Hygiene

Inside Dentistry

ADA News

CDE World

New Dentist News

Conexiant

AACE Endocrinology AI

Conexiant

GI & Hepatology News

The ASCO Post

JADPRO

JNCCN

JNCCN 360

ASCO AI in Oncology

Glaucoma Physician

Ophthalmology Management

Retinal Physician

The Ophthalmologist

Contact Lens Spectrum

Eyecare Business

Optometric Management

The Pathologist

The Medicine Maker

The Analytical Scientist

FDA & Government News

Daily News

Recommendations